HEAL DSpace

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Linardou, H en
dc.contributor.author Dahabreh, IJ en
dc.contributor.author Bafaloukos, D en
dc.contributor.author Kosmidis, P en
dc.contributor.author Murray, S en
dc.date.accessioned 2014-03-01T11:46:24Z
dc.date.available 2014-03-01T11:46:24Z
dc.date.issued 2009 en
dc.identifier.issn 1759-4774 en
dc.identifier.uri https://dspace.lib.ntua.gr/xmlui/handle/123456789/37871
dc.subject.other CELL-LUNG-CANCER en
dc.subject.other GROWTH-FACTOR-RECEPTOR en
dc.subject.other PHASE-III TRIAL en
dc.subject.other GENE COPY NUMBER en
dc.subject.other METASTATIC COLORECTAL-CANCER en
dc.subject.other PREVIOUSLY TREATED PATIENTS en
dc.subject.other GEFITINIB TREATMENT en
dc.subject.other ACQUIRED-RESISTANCE en
dc.subject.other MONOCLONAL-ANTIBODIES en
dc.subject.other PROGNOSTIC INDICATORS en
dc.title Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC en
heal.type other en
heal.language English en
heal.publicationDate 2009 en
heal.abstract Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced rapid, durable, complete or partial responses. These data were the basis for attempts to identify specific subgroups of patients who would further benefit from these agents. The discovery of somatic mutations in EGFR that correlated with sensitivity to TKIs identified a plausible explanation for these observations. Clinical and pathological factors such as female sex, never having smoked, Asian origin and adenocarcinoma histology correlate with the presence of EGFR mutations and objective responses to TKIs in patients with NSCLC. recent studies in metastatic colorectal cancer highlighted that somatic mutations in KRAS represent a negative predictor of response to anti-EGFR monoclonal antibodies; KRAS mutations also represent an important mechanism of resistance to TKIs in NSCLC. Many large clinical studies are currently investigating the predictive and prognostic value of EGFR mutational status and other candidate biomarkers. we summarize the literature and present an overview of the field of anti-EGFR therapy in NSCLC, focusing on the influence of somatic EGFR mutations on selection of patients for TKI therapy and the influence of EGFR pathway regulation. en
heal.publisher NATURE PUBLISHING GROUP en
heal.journalName NATURE REVIEWS CLINICAL ONCOLOGY en
dc.identifier.isi ISI:000266528500010 en
dc.identifier.volume 6 en
dc.identifier.issue 6 en
dc.identifier.spage 352 en
dc.identifier.epage 366 en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record